

Anniina Snellman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/570044/publications.pdf>

Version: 2024-02-01

31
papers

1,582
citations

394421

19
h-index

434195

31
g-index

31
all docs

31
docs citations

31
times ranked

1992
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. <i>Acta Neuropathologica</i> , 2021, 141, 709-724.	7.7	285
2	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. <i>Molecular Psychiatry</i> , 2021, 26, 429-442.	7.9	186
3	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 396.	9.0	146
4	Multifunctional Liposomes Reduce Brain β -Amyloid Burden and Ameliorate Memory Impairment in Alzheimer's Disease Mouse Models. <i>Journal of Neuroscience</i> , 2014, 34, 14022-14031.	3.6	141
5	Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. <i>Brain</i> , 2021, 144, 325-339.	7.6	124
6	Longitudinal Amyloid Imaging in Mouse Brain with ¹¹ C-PIB: Comparison of APP23, Tg2576, and APP ^{swe} -PS1 ^{dE9} Mouse Models of Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1434-1441.	5.0	71
7	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. <i>Journal of Internal Medicine</i> , 2021, 290, 583-601.	6.0	54
8	Pharmacokinetics of [18F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1784-1795.	6.4	52
9	Effects of pre-analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12168.	2.4	52
10	Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. <i>Neurology</i> , 2021, 97, .	1.1	50
11	Prodromal neuroinflammatory, cholinergic and metabolite dysfunction detected by PET and MRS in the TgF344-AD transgenic rat model of AD: a collaborative multi-modal study. <i>Theranostics</i> , 2021, 11, 6644-6667.	10.0	42
12	Neuroinflammation Appears Early on PET Imaging and Then Plateaus in a Mouse Model of Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2018, 59, 509-515.	5.0	40
13	Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 17.	6.2	35
14	Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 69.	6.2	34
15	Chemical exchange saturation transfer MRI shows low cerebral 2-deoxy-D-glucose uptake in a model of Alzheimer's Disease. <i>Scientific Reports</i> , 2018, 8, 9576.	3.3	33
16	Synthesis and evaluation of a 18F-curcumin derivate for β -amyloid plaque imaging. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 2753-2762.	3.0	32
17	p-tau235: a novel biomarker for staging preclinical Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2021, 13, e15098.	6.9	30
18	[18F]FMPEP-d2 PET imaging shows age- and genotype-dependent impairments in the availability of cannabinoid receptor 1 in a mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 69, 199-208.	3.1	23

#	ARTICLE	IF	CITATIONS
19	In vivo PET imaging of beta-amyloid deposition in mouse models of Alzheimer's disease with a high specific activity PET imaging agent [¹⁸ F]flutemetamol. <i>EJNMMI Research</i> , 2014, 4, 37.	2.5	22
20	CSF biomarkers and plasma p-tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design. <i>Alzheimer's and Dementia</i> , 2022, 18, 2614-2626.	0.8	22
21	N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases. <i>Brain</i> , 2022, 145, 2834-2848.	7.6	20
22	Ex Vivo Tracing of NMDA and GABA-A Receptors in Rat Brain After Traumatic Brain Injury Using ¹⁸ F-GE-179 and ¹⁸ F-GE-194 Autoradiography. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1442-1447.	5.0	18
23	Applicability of [¹¹ C]PIB micro-PET imaging for in vivo follow-up of anti-amyloid treatment effects in APP23 mouse model. <i>Neurobiology of Aging</i> , 2017, 57, 84-94.	3.1	17
24	Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. <i>Brain Communications</i> , 2021, 3, fcab073.	3.3	15
25	Effect of genotype and age on cerebral [¹⁸ F]FDG uptake varies between transgenic APPSwe-PS1dE9 and Tg2576 mouse models of Alzheimer's disease. <i>Scientific Reports</i> , 2019, 9, 5700.	3.3	8
26	(S)-[¹⁸ F]THK5117 brain uptake is associated with A β 2 plaques and MAO-B enzyme in a mouse model of Alzheimer's disease. <i>Neuropharmacology</i> , 2021, 196, 108676.	4.1	7
27	ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease " Study Protocol and Baseline Characteristics. <i>Frontiers in Neurology</i> , 2022, 13, 826423.	2.4	7
28	¹⁹ F/ ¹⁸ F exchange synthesis for a novel [¹⁸ F]SIP ₃ radiopharmaceutical. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2013, 56, 385-391.	1.0	6
29	¹⁸ F-labeling syntheses and preclinical evaluation of functionalized nanoliposomes for Alzheimer's disease. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 88, 257-266.	4.0	6
30	6-[¹⁸ F]Fluoro-l-DOPA Uptake in the Rat Pancreas is Dependent on the Tracer Metabolism. <i>Molecular Imaging and Biology</i> , 2014, 16, 403-411.	2.6	2
31	Increased striatal VMAT2 binding in mice after chronic administration of methcathinone and manganese. <i>Brain Research</i> , 2016, 1652, 97-102.	2.2	2